glp-1 and ketosis users on low-carb or keto diets Ketogenic Diets for Body Weight

Press release: Novo Nordisk presents four new analyses on oral semaglutide 25 mg (Wegovy in a pill ) at ObesityWeek 2025, including demonstrated reductions in cardiovascular risk factors.* Retrieved from Rosenstock, J., Hsia, S., Ruiz, L

Due to the above-mentioned effects of TZD on glycemic, hepatic metabolism, and inflammation, treatment with dual-agonism may reduce or reverse liver damage (lobular inflammation, hepatic steatosis, liver cell damage, and fibrosis) and metabolic dysfunction (35, 41)

It belongs to a class of drugs known as GLP-1 (glucagon-like peptide-1) agonists

Inflammation Management : Reduces post-workout inflammation